PointState Capital’s Immunovant IMVT Stock Holding History

PointState Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-46,700	Closed	-$2.16M	–	144
2020 Q4	$2.16M	Buy	+46,700	New	+$2.16M	0.04%	110

Other funds holding IMVT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PointState Capital's IMVT Position: Q1 2021 in Review

PointState Capital sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 46,700 shares — an estimated $2.16M sold.

PointState Capital first reported a position in IMVT in Q4 2020 and held it in 1 quarter. The position peaked at $2.16M in Q4 2020. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

PointState Capital reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
PointState Capital sold 46,700 Immunovant shares in Q1 2021, an estimated $2.16M.
PointState Capital first reported a position in Immunovant in Q4 2020 and held it in 1 quarter.
PointState Capital's Immunovant position peaked at $2.16M in Q4 2020.
120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on PointState Capital's 13F filing for Q1 2021, filed 14 May 2021.